'Green'nanotherapeutics from tea leaves for orally targeted prevention and alleviation of colon diseases
M Zu, D Xie, BSB Canup, N Chen, Y Wang, R Sun… - Biomaterials, 2021 - Elsevier
Although synthesized nanotherapeutics (NTs) are attractive for the oral treatment of colon
diseases, their clinical translations are constrained by the unsatisfactory therapeutic …
diseases, their clinical translations are constrained by the unsatisfactory therapeutic …
Edible ginger-derived nanoparticles: A novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer
There is a clinical need for new, more effective treatments for chronic and debilitating
inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. In this …
inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. In this …
[HTML][HTML] Natural product-based nanomedicine in treatment of inflammatory bowel disease
Many synthetic drugs and monoclonal antibodies are currently in use to treat Inflammatory
Bowel Disease (IBD). However, they all are implicated in causing severe side effects and …
Bowel Disease (IBD). However, they all are implicated in causing severe side effects and …
Oral polyphenol-armored nanomedicine for targeted modulation of gut microbiota–brain interactions in colitis
Developing oral nanomedicines that suppress intestinal inflammation while modulating gut
microbiota and brain interactions is essential for effectively treating inflammatory bowel …
microbiota and brain interactions is essential for effectively treating inflammatory bowel …
Probiotic‐inspired nanomedicine restores intestinal homeostasis in colitis by regulating redox balance, immune responses, and the Gut Microbiome
Microbiota‐based therapeutics offer innovative strategies to treat inflammatory bowel
diseases (IBDs). However, the poor clinical outcome so far and the limited flexibility of the …
diseases (IBDs). However, the poor clinical outcome so far and the limited flexibility of the …
Genistein-derived ROS-responsive nanoparticles relieve colitis by regulating mucosal homeostasis
W Fan, S Zhang, Y Wu, T Lu, J Liu, X Cao… - … Applied Materials & …, 2021 - ACS Publications
Disruption of intestinal homeostasis is an important event in the development of
inflammatory bowel disease (IBD), and genistein (GEN) is a candidate medicine to prevent …
inflammatory bowel disease (IBD), and genistein (GEN) is a candidate medicine to prevent …
[HTML][HTML] Probiotics-loaded nanoparticles attenuated colon inflammation, oxidative stress, and apoptosis in colitis
Promising therapy is needed for treating inflammatory bowel diseases (IBD) to overcome
current treatment that inefficient and associated with unnecessary health risks. Recently, the …
current treatment that inefficient and associated with unnecessary health risks. Recently, the …
[HTML][HTML] Oral administration of turmeric-derived exosome-like nanovesicles with anti-inflammatory and pro-resolving bioactions for murine colitis therapy
Background Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by
diffuse inflammation of the colonic mucosa and a relapsing and remitting course. The current …
diffuse inflammation of the colonic mucosa and a relapsing and remitting course. The current …
Reactive Oxygen Species‐Activated CO Versatile Nanomedicine with Innate Gut Immune and Microbiome Remodeling Effects for Treating Inflammatory Bowel …
Y Zeng, M Fan, Q Zhou, D Chen, T Jin… - Advanced Functional …, 2023 - Wiley Online Library
Abnormal activation of the gut mucosal immune system and a highly dysregulated gut
microbiota play essential roles in the progression of inflammatory bowel disease (IBD). The …
microbiota play essential roles in the progression of inflammatory bowel disease (IBD). The …
An oral pH-activated “nano-bomb” carrier combined with berberine by regulating gene silencing and gut microbiota for site-specific treatment of ulcerative colitis
Ulcerative colitis (UC) is a chronic, relapsing inflammatory bowel disease that features
colonic epithelial barrier dysfunction and gut dysbiosis. Preclinical studies demonstrated that …
colonic epithelial barrier dysfunction and gut dysbiosis. Preclinical studies demonstrated that …